To simply say anyone with a BMI of 27 with a prior heart attack should be treated would be describing a massive number of patients
Significant heterogeneity was observed between insulin and semaglutide recipients regarding ethnicity, age, sex, diagnosis of obesity, certain cardiovascular conditions, and AD-related risk factors
You may wish to monitor more frequently when you start taking this medication
PMCID: PMC5501083
Final Take: Know Your Options, Protect Your Wallet The almost instant success and widespread adoption of semaglutide and other GLP-1s has taken insurance companies, regulators, and federal and state health care programs completely off guard
However, the analysis of the gut microbiota using NGS after a single administration of GLP-1RA has not been studied, and this is a subject for further study